Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

323 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Randomized phase II study of carboplatin plus irinotecan versus carboplatin plus amrubicin in patients with chemo-naïve extensive-stage small-cell lung cancer: North Japan Lung Cancer Study Group (NJLCG) 0901.
Morikawa N, Inoue A, Sugawara S, Maemondo M, Harada T, Harada M, Fujita Y, Katoh T, Yokouchi H, Watanabe H, Usui K, Suzuki T, Sakakibara-Konishi J, Nagai H, Kanbe M, Nukiwa T. Morikawa N, et al. Among authors: yokouchi h. Lung Cancer. 2017 Sep;111:38-42. doi: 10.1016/j.lungcan.2017.06.016. Epub 2017 Jul 1. Lung Cancer. 2017. PMID: 28838395 Clinical Trial.
Analysis of the response and toxicity to gefitinib of non-small cell lung cancer.
Konishi J, Yamazaki K, Kinoshita I, Isobe H, Ogura S, Sekine S, Ishida T, Takashima R, Nakadate M, Nishikawa S, Hattori T, Asahina H, Imura M, Kikuchi E, Kikuchi J, Shinagawa N, Yokouchi H, Munakata M, Dosaka-Akita H, Nishimura M. Konishi J, et al. Among authors: yokouchi h. Anticancer Res. 2005 Jan-Feb;25(1B):435-41. Anticancer Res. 2005. PMID: 15816608 Free article.
A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations.
Asahina H, Yamazaki K, Kinoshita I, Sukoh N, Harada M, Yokouchi H, Ishida T, Ogura S, Kojima T, Okamoto Y, Fujita Y, Dosaka-Akita H, Isobe H, Nishimura M. Asahina H, et al. Among authors: yokouchi h. Br J Cancer. 2006 Oct 23;95(8):998-1004. doi: 10.1038/sj.bjc.6603393. Br J Cancer. 2006. PMID: 17047648 Free PMC article. Clinical Trial.
Randomized phase II trial comparing amrubicin with topotecan in patients with previously treated small-cell lung cancer: North Japan Lung Cancer Study Group Trial 0402.
Inoue A, Sugawara S, Yamazaki K, Maemondo M, Suzuki T, Gomi K, Takanashi S, Inoue C, Inage M, Yokouchi H, Watanabe H, Tsukamoto T, Saijo Y, Ishimoto O, Hommura F, Nukiwa T. Inoue A, et al. Among authors: yokouchi h. J Clin Oncol. 2008 Nov 20;26(33):5401-6. doi: 10.1200/JCO.2008.18.1974. Epub 2008 Oct 14. J Clin Oncol. 2008. PMID: 18854562 Clinical Trial.
Clinical characteristics of pleomorphic carcinoma of the lung.
Ito K, Oizumi S, Fukumoto S, Harada M, Ishida T, Fujita Y, Harada T, Kojima T, Yokouchi H, Nishimura M; Hokkaido Lung Cancer Clinical Study Group. Ito K, et al. Among authors: yokouchi h. Lung Cancer. 2010 May;68(2):204-10. doi: 10.1016/j.lungcan.2009.06.002. Epub 2009 Jul 3. Lung Cancer. 2010. PMID: 19577320 Free article.
A phase II study of amrubicin combined with carboplatin for elderly patients with small-cell lung cancer: North Japan Lung Cancer Study Group Trial 0405.
Inoue A, Ishimoto O, Fukumoto S, Usui K, Suzuki T, Yokouchi H, Maemondo M, Kanbe M, Ogura S, Harada T, Oizumi S, Harada M, Sugawara S, Fukuhara T, Nukiwa T. Inoue A, et al. Among authors: yokouchi h. Ann Oncol. 2010 Apr;21(4):800-803. doi: 10.1093/annonc/mdp384. Epub 2009 Oct 13. Ann Oncol. 2010. PMID: 19825887 Free article. Clinical Trial.
323 results